Peripheral MC1R Activation Modulates Immune Responses and Is Neuroprotective in a Mouse Model of Parkinson's Disease

    December 2023 in “ Journal of Neuroimmune Pharmacology ”
    Pranay Srivastava, Shuhei Nishiyama, Fang Zhou, Sonia Lin, Akriti Srivastava, Chien‐Wen Su, Yuehang Xu, Weiyi Peng, Michaël Levy, Michael A. Schwarzschild, Xiqun Chen
    Image
    Studysummary This study found that systemic administration of NDP-MSH, a melanocortin receptor agonist, provided neuroprotective effects on dopaminergic nigrostriatal neurons in a mouse model of Parkinson's disease, reducing neuroinflammation and suggesting a role for regulatory T cells in these neuroprotective effects.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    The study investigates the effects of NDP-MSH, a synthetic melanocortin receptor agonist, on the immune system and dopaminergic neurons in a mouse model of Parkinson's disease. Systemic administration of NDP-MSH significantly reduced striatal dopamine depletion and dopaminergic neuron loss caused by MPTP and LPS, improved behavioral outcomes, and decreased neuroinflammation, as evidenced by reduced microglial activation and lower levels of TNF-α and IL1β. The neuroprotective effects of NDP-MSH appear to involve the MC1R pathway and are diminished when regulatory T cells (Tregs) are depleted, suggesting Tregs play a role in these effects.
    Discuss this study in the Community →